1-. Hwaid AH, Hasan ASH, Al -Duliami AA, Al-MarjaniMF. Seroprevalence of Helicobacter pylori infection and its relation to abo/rhesus blood groups in Diyala, Iraq. International Journal of Current Research. 2013;5(12):4268–71.
2- Nguyen TN, Barkun AN, Fallone CA, Host determinants of Helicobacter pylori infection and its clinical outcome. Helicobacter. 1999;4(3):18597.
3-.Basso D, Plebani M. H. pylori infection: bacterial virulence factors and cytokine gene polymorphisms as determinants of infection 2004;41(3):31–37.
4-.Posselt G, Backert S, Wessle RS. The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal. 2013;11:77. 26.Kalali B,Mejías-Luque R, Javaheri A, Gerhard M. H. pylori virulence factors: influence on immune system and pathology.Mediators of Inflammation. 2014;2014:426309.
5-.Shiota S, Suzuki R, Yamaoka Y. The significanceof virulence factors in Helicobacter pylori. J Dig Dis.2013;14(7):341–9.
6-.Sgouras DN, Trang TT, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2015;20 Suppl 1:8–16.
7-.Palframan SL, Kwok T, Gabriel K. Vacuolatingcytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesisFrontCell InfectMicrobiol. 2012;2:92.
8-. Foegeding NJ, Caston RR, McClain MS, Ohi MD, Cover TL. An overview of Helicobacter pylori VacA toxin biology. Toxins (Basel). 2016;8(6). pii: E173.
9-.Kononov AV. [Inflammation as abasisforHelicobacterpylor-associated diseases].
10-Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991–1000.
11-.Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international